ClinicalTrials.Veeva

Menu
H

Hautarztpraxis Mortazawi | Remscheid, Germany

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
AMG 451
Guselkumab
JNJ-77242113

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

The co-primary objectives of the study are to:* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Inve...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment u...

Active, not recruiting
Psoriasis
Drug: Guselkumab
Drug: Placebo Injection

Trial sponsors

Amgen logo
AbbVie logo
Janssen (J&J Innovative Medicine) logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems